HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings

This article was originally published in The Tan Sheet

Executive Summary

A bipartisan Senate bill would encourage earlier ANDA filings by generics firms to head off new innovator patent listings and secure sole rights to 180-day exclusivity
Advertisement

Related Content

FDA “Ministerial” Approach To Patent Listings Upheld By Appeals Court
FDA Adds Patent Declaration Forms For Innovators To Generic Final Rule
FDA Patent Listing Criteria Allow Polymorph, Product-By-Process Claims
GPhA Sees Generic Legislation Passing House After S 812 Clears Senate
GPhA Sees Generic Legislation Passing House After S 812 Clears Senate
FTC Backs Single 30-Month Stay On Generic Approvals In Patent Litigation
Senate Generic Drug Bill Would Allow Challenges To Orange Book Listings

Topics

Advertisement
UsernamePublicRestriction

Register

RS128782

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel